Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies

Cancer

Volumn 119, Issue 24, 2013, Pages 4308-4315

  Burnette, Brian L ^a   Dispenzieri, Angela ^a   Kumar, Shaji ^a   Harris, Ann M ^a   Sloan, Jeff A ^a   Tilburt, Jon C ^a   Kyle, Robert A ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

autologous transplant; bortezomib; lenalidomide; maintenance; multiple myeloma; quality of life

Indexed keywords

BORTEZOMIB; LENALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; FATIGUE; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSTAL MAIL; PRIORITY JOURNAL; VERY ELDERLY; YOUNG ADULT;

AUTOLOGOUS TRANSPLANT; BORTEZOMIB; LENALIDOMIDE; MAINTENANCE; MULTIPLE MYELOMA; QUALITY OF LIFE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DATA COLLECTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; QUALITY OF LIFE; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84889883309     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28340     Document Type: Article

References (54)

1. Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. 1988; 57: 94-99.
2. Cohen HJ, Bartolucci AA, Forman WB, Silberman HR,. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol. 1986; 4: 888-899.
3. Report on the second myelomatosis trial after 5 years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults. Br J Cancer. 1980; 42: 813-822.
4. Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults. Br J Cancer. 1980; 42: 823-830.
5. Alexanian R, Balzerzac S, Haut A, et al. Remission maintenance therapy for multiple myeloma. Arch Intern Med. 1975; 135: 147-152.
6. George RP, Poth JL, Gordon D, Schrier SL,. Multiple myeloma-intermittent combination chemotherapy compared to continuous therapy. Cancer. 1972; 29: 1665-1670.
7. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001; 113: 1020-1034.
8. Fritz E, Ludwig H,. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000; 11: 1427-1436.
9. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012; 119: 7-15.
10. Kagoya Y, Nannya Y, Kurokawa M,. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res. 2012; 36: 1016-1021.
11. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1770-1781.
12. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1782-1791.
13. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012; 30: 2946-2955.
14. Sahebi F, Frankel PH, Farol L, et al. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2012; 18: 486-492.
15. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012; 119: 940-948.
16. Mateos MV, Oriol A, Martinez-Lopez J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012; 120: 2581-2588.
17. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012; 120: 9-19.
18. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010; 28: 5101-5109.
19. Ludwig H, Fritz E, Neuda J, Durie BG,. Patient preferences for interferon alfa in multiple myeloma. J Clin Oncol. 1997; 15: 1672-1679.
20. McElwain TJ, Powles RL,. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983; 2: 822-824.
21. Selby P, Zulian G, Forgeson G, et al. The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies. Hematol Oncol. 1988; 6: 173-179.
22. Barlogie B, Dicke KA, Alexanian R,. High dose melphalan for refractory myeloma-the MD Anderson experience. Hematol Oncol. 1988; 6: 167-172.
23. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97.
24. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883.
25. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341: 1565-1571.
26. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357: 2133-2142.
27. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007; 110: 3557-3560.
28. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357: 2123-2132.
29. Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006; 106: 1316-1319.
30. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR,. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24: 431-436.
31. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005; 106: 4050-4053.
32. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005; 129: 776-783.
33. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res. 2004; 10: 8170-8176.
34. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 2609-2617.
35. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100: 3063-3067.
36. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002; 20: 4420-4427.
37. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001; 86: 399-403.
38. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica. 2001; 86: 404-408.
39. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001; 98: 492-494.
40. Maiolino A, Hungria VT, Garnica M, et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol. 2012; 87: 948-952.
41. Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) In patients with multiple myeloma (MM): the NCIC CTG MY.10 Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 39.
42. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009; 27: 1788-1793.
43. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006; 354: 1021-1030.
44. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108: 3289-3294.
45. Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F,. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol. 2009; 83: 279-289.
46. Frodin U, Borjeson S, Lyth J, Lotfi K,. A prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up. Bone Marrow Transplant. 2011; 46: 1345-1352.
47. Porcher R, Levy V, Fermand JP, Katsahian S, Chevret S, Ravaud P,. Evaluating high dose therapy in multiple myeloma: use of quality-adjusted survival analysis. Qual Life Res. 2002; 11: 91-99.
48. Gulbrandsen N, Wisloff F, Brinch L, et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol. 2001; 18: 65-77.
49. Acaster S, Gaugris S, Velikova G, Yong K, Lloyd AJ,. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer. 2012; 21: 599-607.
50. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012; 30: 4249-4255.
51. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366: 1759-1769.
52. Badros AZ,. Lenalidomide in myeloma-a high-maintenance friend. N Engl J Med. 2012; 366: 1836-2838.
53. Kyle RA,. Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy. Mayo Clin Proc. 2011; 86: 419-420.
54. Rajkumar SV,. Haematological cancer: lenalidomide maintenance-perils of a premature denouement. Nat Rev Clin Oncol. 2012; 9: 372-374.